Page 64 - Read Online

Cepas-Guillen et al. Vessel Plus 2021;5:26 Vessel Plus
DOI: 10.20517/2574-1209.2020.79

Review Open Access

Percutaneous treatment of mitral valve disease:

repair vs. replacement

Pedro L. Cepas-Guillen, Eduardo Flores-Umanzor, Ander Regueiro, Xavier Freixa
Department of Cardiology, Hospital Clinic of Barcelona, IDIBAPS, University of Barcelona, Barcelona 8009, Spain.

Correspondence to: Dr. Xavier Freixa, Hospital Clinic of Barcelona, c/Villarroel 170, Escala 3, Planta 6, 08015 Barcelona, Spain.
E-mail: Freixa@clinic.cat

How to cite this article: Cepas-Guillen PL, Flores-Umanzor E, Regueiro A, Freixa X. Percutaneous treatment of mitral valve
disease: repair vs. replacement. Vessel Plus 2021;5:26. https://dx.doi.org/10.20517/2574-1209.2020.79

Received: 1 Dec 2020 First Decision: 4 Jan 2021 Revised: 16 Jan 2021 Accepted: 29 Jan 2021 Published: 17 May 2021

Academic Editor: Manel Sabate Copy Editor: Yue-Yue Zhang Production Editor: Xi-Jun Chen

Abstract
Severe mitral regurgitation is the second leading cause of cardiac valve intervention in Europe, reaching up to 10%
of people older than 75 years. The mitral valve is an anatomically complex structure in which several underlying
mechanisms for its malfunction could coexist. Nonetheless, over the last years, development of new techniques
and devices, improved patient selection, and dedicated imaging assessment and guidance tools seem to offer novel
alternatives for percutaneous mitral valve treatment. The present review aims to provide an update of the available
percutaneous techniques for patients with severe mitral regurgitation.

Keywords: Mitral regurgitation, percutaneous techniques

INTRODUCTION
Severe mitral regurgitation (MR) is the second leading cause of cardiac valve intervention in Europe,
[1]
reaching up to 10% of people older than 75 years . Mitral valve (MV) surgery remains the gold standard of
care for patients with symptomatic severe primary MR . However, aging, a higher incidence of
[2]
comorbidities, and frailty in patients with secondary MR have made necessary the development of new
minimally invasive percutaneous techniques. These techniques have improved the prognosis of untreated
[3]
patients with severe MR in whom mortality rates could reach 50% .The MV is an anatomically complex
structure in which several underlying mechanisms for its malfunction could coexist. This complex anatomy
is probably the main reason why percutaneous management of the MV has not expanded as much as that of

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing,
adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as
long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and
indicate if changes were made.

www.vpjournal.net